VivoSeq
Oncology

Endometrial Carcinoma

56

Pipeline Programs↗

15

Active Trials↗

29

Companies Involved↗

Endometrial Carcinoma is a moderately active landscape with 56 programs across 29 companies. The most active players are Novartis, Merck & Co., Bristol-Myers Squibb. 2 therapies are approved with 11 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

62/100

Pipeline Velocity

15/100

Mech. Concentration

9/100

Completion Rate

77/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

4 programs

Phase 2Merck & Co. logo

Merck & Co.

3 programs

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

3 programs

Phase 2Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

2 programs

Phase 2Sanofi logo

Sanofi

1 program

Phase 2Incyte logo

Incyte

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

77%

Small molecule

48 of 62 classified programs — the dominant modality here.

23%ALL OTHERSMonoclonal antibody1219%Antibody–drug conjugate12%Protein / enzyme12%

Small molecule leads; the ring shows all 62 classified programs, each share of the total. Modality classified for 98% of 63 pipeline programs.

Analysis

Trial Status

47

clinical trials

Completed20 · 43%
Recruiting7 · 15%
Unknown status6 · 13%
Active, not recruiting6 · 13%
Withdrawn4 · 9%
Not yet recruiting2 · 4%
Other2 · 4%

Clinical Trials

Trial Activity

47 trials

Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma
Recruiting·—·Phase 1·NCT05603910·18 enrolled
Prospective Study for Endometrial Carcinoma and Hyperplasia in Childbearing-age Women
Recruiting·WWomen's Hospital School Of Medicine Zhejiang University·N/A·NCT06417736·75 enrolled
Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma
Recruiting·SShandong Cancer Hospital and Institute·Phase 2·NCT06532539·30 enrolled
Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification
Recruiting·FFudan University·Phase 2/3·NCT07319429·260 enrolled
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Recruiting·KKaryopharm Therapeutics Inc·Phase 3·NCT05611931·276 enrolled
Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study
Recruiting·—·Phase 1/2·NCT04014530·47 enrolled
Acceptability of Testing DNA Markers in Vaginal Fluid for the Detection of Endometrial Cancer
Recruiting·MMayo Clinic·N/A·NCT07527143·25 enrolled
A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma
Active, not recruiting·YYale University·Phase 2·NCT04251416·50 enrolled
The Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma
Active, not recruiting·—·Phase 3·NCT01820858·300 enrolled
A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma
Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT03008408·90 enrolled
Evaluation of Sentinel Node Policy in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence.
Active, not recruiting·CCentre Oscar Lambret·Phase 3·NCT02598219·262 enrolled
A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma
Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT01797523·62 enrolled
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
Active, not recruiting·Merck & Co. logoMerck & Co.·Phase 3·NCT05173987·280 enrolled
Combination Chemotherapy of Paclitaxel and Carboplatin With or Without Anthracycline as Aneo Adjuvant Treatment in Advanced Endometrial Carcinoma
Not yet recruiting·SSohag University·N/A·NCT06102252·80 enrolled
A Phase 1a/b Study to Evaluate the Safety and Efficacy of OPB 201, an Autologous PReferentially Expressed Antigen of MElanoma (PRAME) T Cell Receptor (TCR) T Cell Therapy in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.
Not yet recruiting·OOutpace Bio, Inc.·Phase 1·NCT07664735·30 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)